prikaz prve stranice dokumenta Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke
  Preuzmi
PDF 331.84 KB
Znanstveni rad - Izvorni znanstveni rad
Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke
Journal of the Neurological Sciences, 343 (2014), 1-2; 30-35. https://doi.org/10.1016/j.jns.2014.04.039
Šupe, Svjetlana; Božina, Nada; Matijević, Vesna; Bazina, Antonela; Mišmaš, Antonija; Ljevak, Josip; Alvir, Domagoj; Habek, Mario; Poljaković, Zdravka

Citirajte ovaj rad

Šupe, S., Božina, N., Matijević, V., Bazina, A., Mišmaš, A., Ljevak, J. ... Poljaković, Z. (2014). Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke. Journal of the Neurological Sciences, 343. (1-2), 30-35. doi: 10.1016/j.jns.2014.04.039

Šupe, Svjetlana, et al. "Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke." Journal of the Neurological Sciences, vol. 343, br. 1-2, 2014, str. 30-35. https://doi.org/10.1016/j.jns.2014.04.039

Šupe, Svjetlana, Nada Božina, Vesna Matijević, Antonela Bazina, Antonija Mišmaš, Josip Ljevak, Domagoj Alvir, Mario Habek i Zdravka Poljaković. "Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke." Journal of the Neurological Sciences 343, br. 1-2 (2014): 30-35. https://doi.org/10.1016/j.jns.2014.04.039

Šupe, S., et al. (2014) 'Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke', Journal of the Neurological Sciences, 343(1-2), str. 30-35. doi: 10.1016/j.jns.2014.04.039

Šupe S, Božina N, Matijević V, Bazina A, Mišmaš A, Ljevak J, i sur.. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke. Journal of the Neurological Sciences [Internet]. 15.08.2014. [pristupljeno 14.04.2024.];343(1-2):30-35. doi: 10.1016/j.jns.2014.04.039

S. Šupe, et al., "Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke", Journal of the Neurological Sciences, vol. 343, br. 1-2, str. 30-35, Kolovoz 2014. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:948851. [Citirano: 14.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:948851
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke
AutorSvjetlana Šupe
AutorNada Božina
AutorVesna Matijević
AutorAntonela Bazina
AutorAntonija Mišmaš
AutorJosip Ljevak
AutorDomagoj Alvir
AutorMario Habek
AutorZdravka Poljaković
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
BACKGROUND: Data on the prevalence of CYP2C9 and VKORC1 genes and their influence on anticoagulant effect and warfarin dose in stroke patients are scarce. The aim of this study was to determine the occurrence and significance of these gene polymorphisms and to establish pharmacogenetic algorithm to estimate the dose of introduction. Also, the goal was to determine tailored safety and intensity of anticoagulation response depending on the allelic variants and their impact on the clinical outcome in acute stroke patients in Croatia. ----- METHODS: A total of 106 consented acute stroke patients were tested for CYP2C9 2, 3 and VKORC1 1173C>T gene polymorphisms. We estimated the dose of introduction and monitored anticoagulant effect obtained by INR values, time to reach stable dose, stable maintenance dose, time spent within the therapeutic/supratherapeutic INR range, occurrence of dosage side effects and clinical outcome depending on genotypes. ----- RESULTS: We found that 83% of stroke patients in our study were carriers of multiple allelic variants. The predicted initial dose correlated with the stable warfarin maintenance dose (p=0.0311) and we correctly estimated the dose for 81.5% of 61.3% of study patients who required higher/lower doses than average. Warfarin dosage complications were slightly more frequent among the carriers of CYP2C9 2, 3 compared to the carriers of VKORC1 1173T alleles (68. 9% versus 62.5%), but their occurrence did not affect the final clinical outcome. ----- CONCLUSION: Our data indicated rapid and safe anticoagulation achieved by using pharmacogenetically-predicted warfarin dose in high-risk acute stroke patients without increasing the risk of warfarin dosage complications in an elderly population.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaJournal of the Neurological Sciences
Brojčani podacivol. 343, br. 1-2, str. 30-35
p-ISSN0022-510X
DOIhttps://doi.org/10.1016/j.jns.2014.04.039
URN:NBNurn:nbn:hr:105:948851
Datum objave publikacije2014-08-15
URL dokumentahttps://doi.org/10.1016/j.jns.2014.04.039
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 08:03:47